Amylyx Pharmaceuticals

Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results

Retrieved on: 
木曜日, 5月 9, 2024
Research, FDA, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Investment, Webcast, IND, WFS1, TDP43, AMX0035, Diabetes, Samuel, CSF, Biomarker, Astellas Pharma, Disclosure, Brain, Food, Amylyx Pharmaceuticals, Endoplasmic reticulum, Health Canada, Tauopathy, ALS, Eli Lilly and Company, FCCP, Medication, Merck, Cerebrospinal fluid, Safety, PB, Neurological disorder, Genetic linkage, Week, Wolfram syndrome, C-peptide, DSM-IV codes, Drug development, Clinical trial, Walking, Division, MD, Patient, Disease, Regulation Fair Disclosure, Principal, Regulation, PGIC, Metabolism, Interim, FACP, Pharmaceutical industry

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the first quarter ended March 31, 2024.
  • This decision was informed by topline PHOENIX trial results, engagement with regulatory authorities, and discussions with the ALS community.
  • Amylyx anticipates reporting topline data from all 12 participants at Week 24 in the fall of 2024.
  • Amylyx’ management team will host a conference call and webcast today, May 9, 2024, at 8:00 a.m.

Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference

Retrieved on: 
水曜日, 5月 8, 2024
Health, Neurology, Research, Pharmaceutical, Science, Biotechnology, MD, Medication, Bank, Conference, Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, and Camille L. Bedrosian, MD, Chief Medical Officer of Amylyx, will participate in the 2024 Bank of America Health Care Conference.

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, and Camille L. Bedrosian, MD, Chief Medical Officer of Amylyx, will participate in the 2024 Bank of America Health Care Conference.
  • The conference is being conducted in-person in Las Vegas, Nevada, and the fireside chat will take place on Wednesday, May 15, 2024, at 8:40 a.m. PT/11:40 a.m.
  • ET.
  • A live webcast of the presentation can be accessed under “Events” in the Investor section of the Company’s website, https://investors.amylyx.com/news-events/events , and will be available for replay for 90 days following the event.

Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024

Retrieved on: 
木曜日, 5月 2, 2024
Finance, Neurology, Health, Professional Services, Pharmaceutical, Amylyx Pharmaceuticals, Medication, Webcast

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its first quarter 2024 financial results on Thursday, May 9, 2024.

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its first quarter 2024 financial results on Thursday, May 9, 2024.
  • Amylyx’ senior management team will host a conference call and audio webcast at 8:00 a.m.
  • ET to discuss the financial results and other company updates.
  • A live audio webcast of the call will be available under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/news-events/events .

Obsidian Therapeutics Appoints Jeffrey Trigilio as Chief Financial Officer

Retrieved on: 
月曜日, 4月 15, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Credit Suisse, Corporate finance, RBC Capital Markets, Amylyx Pharmaceuticals, Alexion Pharmaceuticals, Cornell University, TIL, Record, Columbia Business School, Therapy, Growth

Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Jeffrey Trigilio as Chief Financial Officer, effective May 1, 2024.

Key Points: 
  • Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Jeffrey Trigilio as Chief Financial Officer, effective May 1, 2024.
  • “We are thrilled to welcome Jeff to the Obsidian leadership team as the company’s Chief Financial Officer,” said Madan Jagasia, M.D., Chief Executive Officer of Obsidian.
  • Most recently, he served as Chief Financial Officer of Cullinan Oncology, where he guided its initial public offering and helped secure several business development transactions for its portfolio.
  • Before Cullinan, Mr. Trigilio served as Chief Financial Officer for Amylyx Pharmaceuticals, Vice President of Corporate Finance at BlueRock Therapeutics, and in various corporate strategy and finance roles at Alexion Pharmaceuticals.

Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome

Retrieved on: 
水曜日, 4月 10, 2024
Health, Diabetes, Neurology, Genetics, Clinical Trials, Pharmaceutical, FDA, DSM-IV codes, Glycated hemoglobin, Cell, Safety, PB, Blood, Apoptosis, Paratriathlon, C-peptide, Endoplasmic reticulum, Doctor of Philosophy, WFS1, Disease, AMX0035, Week, Wolfram syndrome, Science, Snellen, Patient, Diarrhea, Amylyx Pharmaceuticals, Data analysis, PGIC, Samuel, Metabolism, Aes, Visual acuity, Clinical trial, AUC, Medication, Division, Pharmaceutical industry

“I have been studying Wolfram syndrome and caring for people with the disease for more than 20 years.

Key Points: 
  • “I have been studying Wolfram syndrome and caring for people with the disease for more than 20 years.
  • Outcomes for people with Wolfram syndrome consistently worsen over time, so disease stabilization alone is clinically meaningful for both patients and their doctors.
  • Because of the clear link between WFS1 mutations and ER stress, Wolfram syndrome is considered a prototypical ER stress disorder.
  • Amylyx announced that the FDA granted orphan drug designation to AMX0035 for the treatment of Wolfram syndrome in November 2020.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100k to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX

Retrieved on: 
金曜日, 3月 29, 2024
Titan, Plaintiff, ALS, Patient, AMX0035, Class, Amylyx Pharmaceuticals, Advertising, Court

WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100k to Secure Counsel Before Important Deadline in Securities Class Action - AMLX

Retrieved on: 
火曜日, 3月 26, 2024
Titan, Plaintiff, ALS, Patient, AMX0035, Class, Amylyx Pharmaceuticals, Advertising, Court

WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

ROSEN, A LONGSTANDING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLX

Retrieved on: 
土曜日, 3月 23, 2024
Titan, Plaintiff, ALS, Patient, AMX0035, Class, Amylyx Pharmaceuticals, Advertising, Court

WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLX

Retrieved on: 
木曜日, 3月 14, 2024
Titan, Plaintiff, ALS, Patient, AMX0035, Class, Amylyx Pharmaceuticals, Advertising, Court

WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Amylyx Pharmaceuticals, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; April 9, 2024 deadline

Retrieved on: 
月曜日, 4月 8, 2024
Amylyx Pharmaceuticals, Patient, Defendant, Apoptosis, ALS, Pharmaceutical industry

LOS ANGELES, April 08, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors that a lawsuit was filed on behalf of investors that purchased Amylyx securities between November 11, 2022 and November 8, 2023, inclusive (the “Class Period”).

Key Points: 
  • LOS ANGELES, April 08, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) investors that a lawsuit was filed on behalf of investors that purchased Amylyx securities between November 11, 2022 and November 8, 2023, inclusive (the “Class Period”).
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 310-692-8883 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.